

BIOCON GROUP

FACT SHEET

March - 2025

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			(Rs. Crores)
Particulars	Q4 FY 25	Q4 FY 24	Variance %
<u>INCOME</u>			
Generics	1,048	718	46%
Biosimilars	2,463	2,358	4%
Research services	1,018	917	11%
Inter-segment	(112)	(76)	47%
Revenue from operations #	4,417	3,917	13%
Other income	37	49	-24%
TOTAL REVENUE	4,454	3,966	12%
<u>EXPENDITURE</u>			
Material & Power costs	1,567	1,417	11%
Staff costs	765	532	44%
Research & Development expenses*	231	246	-6%
Other expenses	776	806	-4%
Manufacturing, staff & other expenses	3,339	3,001	11%
EBITDA	1,115	964	16%
Interest & Finance charges	212	227	-6%
Depreciation & Amortisation	436	407	7%
Share of loss / (profit) in JV / Associate, net	-	3	-100%
PBT	466	328	42%
Exceptional items, net	21	(9)	-333%
PBT	487	319	53%
Taxes	24	98	-75%
Taxes on exceptional item	4	(2)	-233%
NET PROFIT BEFORE MINORITY INTEREST	459	223	106%
Minority interest	109	87	25%
Minority interest on exceptional item	6	-	100%
NET PROFIT FOR THE PERIOD	344	136	154%
EPS Rs.	2.9	1.1	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	333	144	132%
Exceptional item, net of taxes	11	(8)	-147%
NET PROFIT FOR THE PERIOD	344	136	153%
<i># Licensing Income</i>	8	15	
<i>* Gross Research & Development expenses</i>	231	228	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			
(Rs. Crores)			
Particulars	Q4 FY 25	Q3 FY 25	Variance %
INCOME			
Generics	1,048	686	53%
Biosimilars	2,463	2,289	8%
Research services	1,018	944	8%
Inter-segment	(112)	(98)	15%
Revenue from operations #	4,417	3,821	16%
Other income	37	35	6%
TOTAL REVENUE	4,454	3,856	15%
EXPENDITURE			
Material & Power costs	1,567	1,454	8%
Staff costs	765	731	5%
Research & Development expenses*	231	199	16%
Other expenses	776	686	13%
Manufacturing, staff & other expenses	3,339	3,069	9%
EBITDA	1,115	787	42%
Interest & Finance charges	212	223	-5%
Depreciation & Amortisation	436	425	3%
PBT BEFORE EXCEPTIONAL ITEM	466	138	238%
Exceptional item, net	21	18	-100%
PBT	487	156	212%
Taxes	24	72	-67%
Taxes on exceptional item	4	3	17%
NET PROFIT BEFORE MINORITY INTEREST	459	81	467%
Minority interest	109	53	106%
Minority interest on exceptional item	6	3	-
NET PROFIT FOR THE PERIOD	344	25	1272%
EPS Rs.	2.9	0.2	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	333	13	2426%
Exceptional item	11	12	
NET PROFIT FOR THE PERIOD	344	25	1272%
<i># Licensing Income</i>	8	7	
<i>* Gross Research & Development expenses</i>	231	199	

BIOCON LIMITED (CONSOLIDATED)			(Rs. Crores)
PROFIT & LOSS STATEMENT			
Particulars	FY 25	FY24	Variance %
INCOME			
Generics	3,017	2,799	8%
Biosimilars	9,017	8,824	2%
Research services	3,642	3,489	4%
Inter-segment	(416)	(356)	17%
Revenue from operations #	15,262	14,756	3%
Other income	1,208	866	40%
TOTAL REVENUE	16,470	15,621	5%
EXPENDITURE			
Material & Power costs	5,575	5,287	5%
Staff costs	2,944	2,137	38%
Research & Development expenses*	859	1,154	-26%
Other expenses	2,717	2,879	-6%
Manufacturing, staff & other expenses	12,096	11,457	6%
EBITDA	4,374	4,164	5%
Interest & Finance charges	897	974	-8%
Depreciation & Amortisation	1,687	1,569	8%
Share of loss / (profit) in JV / Associate, net	-	84	100%
PBT BEFORE EXCEPTIONAL ITEM	1,790	1,537	16%
Exceptional item, Net	97	(12)	-
PBT	1,887	1,525	24%
Taxes	416	231	80%
Taxes on exceptional item	21	(3)	-
Deferred tax charge on withdrawal of indexation benefit	20	-	0%
NET PROFIT BEFORE MINORITY INTEREST	1,429	1,298	10%
Minority interest	393	276	42%
Minority interest on exceptional item	23	(1)	-
NET PROFIT FOR THE PERIOD	1,013	1,022	-1%
EPS Rs.	8.4	8.5	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	981	1,030	-5%
Exceptional item, net of taxes	32	(8)	-
NET PROFIT FOR THE PERIOD	1,013	1,022	-1%
<i># Licensing Income</i>	<i>34</i>	<i>193</i>	
<i>* Gross Research & Development expenses</i>	<i>859</i>	<i>1,161</i>	

BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET

(Rs Crores)

Particulars	Mar 31, 2025	Mar 31, 2024
ASSETS		
Non-current assets		
(a) Property, plant and equipment	8,708	7,418
(b) Capital work-in-progress	4,102	3,985
(c) Right-of-use assets	604	575
(d) Goodwill	16,786	16,372
(e) Other intangible assets	5,865	6,279
(f) Intangible assets under development	4,407	4,008
(g) Financial assets		
Investments	680	684
Derivative assets	187	266
Other financial assets	68	147
(i) Income tax asset, net	371	413
(j) Deferred tax asset, net	258	317
(k) Other non-current assets	475	428
Non-current assets	42,511	40,892
Current assets		
(a) Inventories	4,931	4,944
(b) Financial assets		
Investments	447	316
Trade receivables	5,488	6,231
Cash and cash equivalents	3,227	1,234
Other bank balances	893	1,025
Derivative assets	96	138
Other financial assets	456	577
(c) Other current assets	748	714
Current assets	16,286	15,179
TOTAL - ASSETS	58,797	56,071
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	600	600
(b) Other equity	21,044	19,184
Equity attributable to owners of the Company	21,644	19,784
Non-controlling interests	6,068	5,491
Total Equity	27,712	25,275
Non-current liabilities		
(a) Financial liabilities		
Borrowings	12,405	12,932
Lease liabilities	539	492
Derivative liabilities	23	-
Other financial liabilities	2,828	1,073
(b) Other non-current liabilities	337	310
(c) Provisions	261	238
(d) Deferred tax liability, net	358	392
Non-current liabilities	16,751	15,437
Current liabilities		
(a) Financial liabilities		
Borrowings	5,350	2,797
Lease liabilities	67	55
Trade payables	6,549	6,272
Derivative liabilities	46	1
Other financial liabilities	933	5,001
(b) Other current liabilities	1,024	776
(c) Provisions	192	180
(d) Income tax liability, net	173	277
Current liabilities	14,334	15,359
TOTAL - EQUITY AND LIABILITIES	58,797	56,071